Skip to main content

Peer Review reports

From: TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma

Original Submission
9 Jun 2022 Submitted Original manuscript
23 Jul 2022 Reviewed Reviewer Report
18 Aug 2022 Reviewed Reviewer Report
29 Aug 2022 Author responded Author comments - Xiangwen Xia
Resubmission - Version 2
29 Aug 2022 Submitted Manuscript version 2
1 Sep 2022 Author responded Author comments - Xiangwen Xia
Resubmission - Version 3
1 Sep 2022 Submitted Manuscript version 3
10 Oct 2022 Author responded Author comments - Xiangwen Xia
Resubmission - Version 4
10 Oct 2022 Submitted Manuscript version 4
6 Nov 2022 Reviewed Reviewer Report
23 Nov 2022 Author responded Author comments - Xiangwen Xia
Resubmission - Version 5
23 Nov 2022 Submitted Manuscript version 5
8 Dec 2022 Reviewed Reviewer Report
11 Jan 2023 Reviewed Reviewer Report
2 Feb 2023 Author responded Author comments - Xiangwen Xia
Resubmission - Version 6
2 Feb 2023 Submitted Manuscript version 6
28 Feb 2023 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
1 Mar 2023 Editorially accepted
13 Mar 2023 Article published 10.1186/s12885-023-10694-9

You can find further information about peer review here.

Back to article page